NewVac, Janssen sign co-license agreement to develop quisinostat
As per the deal, NewVac gains exclusive rights to develop and commercialize Janssen’s quisinostat in Russia and other Eastern European countries. NewVac board chairman Nikolay Savchuk said the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.